Global Neurocognitive DisorderTreatment Market: Market Dynamics
Increasing prevalence ofneurocognitive disorder is expected to augment the global NeurocognitiveDisorder Treatment Market growth. Due to advancement in technology andinventions such as Al and adoption of unhealthy work practices, increasedcardiovascular issues are boosting the global neurocognitive disorder market.Moreover, increased addiction of drugs and alcohol in youth and also changingclimate conditions or respiratory diseases are causing neurocognitive disordersand driving the market growth. Furthermore, increase in number of geriatricpopulation is also the factor affecting the market growth. Approvals of thedrugs associated with the treatment from the regulatory bodies is the factorthat drives the market growth. For instance, on April 11, 2019, the U.S.FDAaccepted the resubmitted new drug application (NDA) for instradefylline(KW-6002), which is an oral selective adenosine receptor antagonist for use asadjunctive treatment for Parkinson’s disease in adults. On May 20, 2019, theU.S.FDA approved Neuronascent Investigational New Drug (IND) application forNNI-362.
The clinical trials of some drugsare terminated, as they are not able to reach to their primary endpoint. Forinstance, on March 21, 2019, Biogen and Eisei, Co., Ltd announced the decisionto discontinue the global phase 3 trial of Aducanumab, which is designed toevaluate the safety and efficacy of an antibody-aducanumab in patients withAlzheimer disease. This decision to stop the trial is based on the analysisthat trials were unlikely to improve the people’s memory and thinkingsufficiently by the end of the trial. This discontinuation of trials is themajor restraining factor for the market.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2676
Neurocognitive disorders includedementia, delirium, and mild cognitive impairment, which is characterized bydecline of the level of cognitive functioning. Neurocognitive deficit is areduction or impairment of cognitive functions and affects nerve cells andoften impact the person’s ability to remember, to reason, and to makejudgments. The neurocognitive disorders have different clinical characteristicswith Alzheimer disease, front temporal degeneration, cerebrovascular disease,traumatic brain injury, Lewy body disease, and infections showing the commoncauses. Alzheimer disease is the most common cause of neurocognitive disorder.In the early stages of Alzheimer, people are not able to remember the recentevents, conversations, and names of people and may also experience thedepression. Individuals with neurocognitive disorder show the side effects likemood disturbances including apathy, depression, anxiety and sleep disturbance includinginsomnia, hypersomnia.
Neurocognitive disorder treatmentsinclude pain medications, surgeries, physical therapy, bed rest, and others.Furthermore, for treatment of neurocognitive disorder, antibiotics are used toclear the remaining infections, which is affecting the brain, such asmeningitis.
Global Neurocognitive DisorderTreatment Market: Regional Dynamics
North America is expected to holda dominant position in the global neurocognitive disorder treatment market,owing to adoption of advanced technology and rising number of neurocognitivedisorder patients. According to the World Health Organization (WHO), nearly35.6 million people live with dementia worldwide. The number of geriatricpopulation worldwide and related dementia patients is expected to rise up to65.7 million in 2030 and 115.4million in 2050. Furthermore, according WHO, theprevalence of dementia is increasing exponentially with age and sex in NorthAmerica region, doubling in every 5.5 years. Moreover, satisfactoryreimbursement policies, rising adoption of advance precautious methods andincreasing penetration of life science analytics for monitoring health changescontinuously are factors driving the growth of market in North America.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/neurocognitive-disorder-treatment-market-2676
Global Neurocognitive DisorderTreatment Market: Competitive Landscape
The key players in globalneurocognitive disorder treatment market are focusing on developing innovative,new, and efficient neurocognitive disorder treatment drugs that are launched inthe market to meet the demand from consumers for various types ofneurocognitive disorder treatments. For instance, in March 2018, Biogenannounced to enter into an agreement to acquire Pfizer Inc. phase 2b ready AMPAreceptor potentiator for cognitive impairment.
Furthermore, in May 2019, T3Dtherapeutics received grant of US$ 9 million from National Institute on Aging(NIA) to develop drug T3D-959 for neurocognitive disease.
Key players operating in theglobal neurocognitive disorder treatment market include A B Science, Abbive, AC immune, Biogen, Eisai, Immunobrain, Mediti Pharma Inc., Ono Pharmaceuticals,Proclar Biosciences, Problodrug AG, Roche, T3D Therapeutics, and PurduePharma.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2676
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related to emergingmarket trends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
